سعر انديكويبين 200 مجم 20 قرص 2022

Extended-release film-coated tablets containing quetiapine 200 mg (Al Andalous Pharmaceutical Industries); 20 tablets per pack.

• SchizophreniaPopulation: Adults and adolescents 13-17 yearsDailyMed (U.S. National Library of Medicine)
• Bipolar I disorder, manic or mixed episodes (monotherapy or adjunct to lithium or divalproex)Population: Adults; monotherapy for mania in children 10-17 yearsDailyMed (U.S. National Library of Medicine)
• Depressive episodes associated with bipolar disorderPopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Most common in short-term adult schizophrenia trials (≥5% and at least twice placebo): somnolence (25%), dry mouth (12%), dizziness (10%), dyspepsia (5%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to quetiapine or any excipient (anaphylactic reactions reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: increased mortality in elderly patients with dementia-related psychosis; not approved for this use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Boxed warning: increased risk of suicidal thoughts and behaviours in children, adolescents and young adults taking antidepressants; monitor for clinical worsening and emergence of suicidal thoughts and behaviours.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other warnings: neuroleptic malignant syndrome, metabolic changes (hyperglycaemia, dyslipidaemia, weight gain), tardive dyskinesia, orthostatic hypotension and falls, leukopenia/neutropenia/agranulocytosis, cataracts, QT prolongation, seizures, hypothyroidism, hyperprolactinaemia, somnolence, dysphagia, withdrawal symptoms, anticholinergic effects.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, nefazodone)Reduce quetiapine dose to one-sixth; increase 6-fold when the inhibitor is stopped.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, St John's wort)Quetiapine dose may need to be increased up to 5-fold with chronic inducer use.DailyMed (U.S. National Library of Medicine)
• Alcohol and other centrally acting drugsQuetiapine potentiated the cognitive and motor effects of alcohol; avoid alcohol and use caution with CNS drugs.DailyMed (U.S. National Library of Medicine)

• Epidemiologic data have not established a drug-associated risk of major birth defects; weigh risks of untreated psychiatric illness.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Present in human milk at a relative infant dose below 1%; no consistent adverse effects reported in breastfed infants.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Quetiapine (salt form not stated): Mechanism unclear; efficacy may be mediated by combined dopamine D2 and serotonin 5-HT2A receptor antagonism (active metabolite norquetiapine has greater 5-HT2A activity).